Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: A 4 week randomized multicentre controlled trial

Se Hwa Yoo, Sung Hak Park, Jeong Sup Song, Kyung Ho Kang, Choon Sik Park, Jee Hong Yoo, Byoung Whui Choi, Myung Ho Hahn

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalRespirology
Volume6
Issue number1
DOIs
Publication statusPublished - 2001 May 9

Fingerprint

Leukotriene Antagonists
Multicenter Studies
Asthma
Randomized Controlled Trials
Leukotriene Receptors
Placebos
pranlukast
Vital Capacity
Forced Expiratory Volume
Korea
Adrenal Cortex Hormones
Clinical Trials
Safety

Keywords

  • Leukotriene receptor antagonist
  • Mild-to-moderate asthma
  • Pranlukast
  • Randomized clinical trial

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma : A 4 week randomized multicentre controlled trial. / Yoo, Se Hwa; Park, Sung Hak; Song, Jeong Sup; Kang, Kyung Ho; Park, Choon Sik; Yoo, Jee Hong; Choi, Byoung Whui; Hahn, Myung Ho.

In: Respirology, Vol. 6, No. 1, 09.05.2001, p. 15-21.

Research output: Contribution to journalArticle

Yoo, Se Hwa ; Park, Sung Hak ; Song, Jeong Sup ; Kang, Kyung Ho ; Park, Choon Sik ; Yoo, Jee Hong ; Choi, Byoung Whui ; Hahn, Myung Ho. / Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma : A 4 week randomized multicentre controlled trial. In: Respirology. 2001 ; Vol. 6, No. 1. pp. 15-21.
@article{7590eec4af134283b17525fb6c92e7eb,
title = "Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: A 4 week randomized multicentre controlled trial",
abstract = "Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.",
keywords = "Leukotriene receptor antagonist, Mild-to-moderate asthma, Pranlukast, Randomized clinical trial",
author = "Yoo, {Se Hwa} and Park, {Sung Hak} and Song, {Jeong Sup} and Kang, {Kyung Ho} and Park, {Choon Sik} and Yoo, {Jee Hong} and Choi, {Byoung Whui} and Hahn, {Myung Ho}",
year = "2001",
month = "5",
day = "9",
doi = "10.1046/j.1440-1843.2001.00291.x",
language = "English",
volume = "6",
pages = "15--21",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma

T2 - A 4 week randomized multicentre controlled trial

AU - Yoo, Se Hwa

AU - Park, Sung Hak

AU - Song, Jeong Sup

AU - Kang, Kyung Ho

AU - Park, Choon Sik

AU - Yoo, Jee Hong

AU - Choi, Byoung Whui

AU - Hahn, Myung Ho

PY - 2001/5/9

Y1 - 2001/5/9

N2 - Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.

AB - Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.

KW - Leukotriene receptor antagonist

KW - Mild-to-moderate asthma

KW - Pranlukast

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0035026972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035026972&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1843.2001.00291.x

DO - 10.1046/j.1440-1843.2001.00291.x

M3 - Article

C2 - 11264758

AN - SCOPUS:0035026972

VL - 6

SP - 15

EP - 21

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 1

ER -